Resumen:
INTRODUCTION: Flow cytometry (FC) is a helpful tool for the diagnosis of
myelodysplastic syndrome (MDS). Different FC score systems have been developed.
The "Ogata score" is a simple diagnostic score that has been validated having a
sensitivity of 69% and a specificity of 92% in low-risk MDS. We aimed to study
the feasibility and the utility of the "Ogata score" for the diagnosis of MDS
among Latin America (LA) Laboratories. METHODS: This is a case and control study
conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia
(GLAM). A total of 146 MDS patients and 57 control patients were included. "Ogata
score" was calculated. RESULTS: The sensitivity of "Ogata score" was 75.6% (95%
CI, 66.8-81.3), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 95.6% (95% CI,
88.5-98.3), and NPV was 65.4% (95% CI, 49.1-71.9). In low/intermediate-1 IPSS
patients group, the sensitivity was 70.1% (95% CI, 60.2-78.2), specificity was
91.2% (CI-95%, 79.7-96.7), PPV was 94.2% (95% CI, 86.4-97.8), and NPV was 62.1%
(95% CI, 53.0-78.7). In the group of patients "without MDS specific markers"
(patients without ring sideroblasts, blast excess, or chromosomal abnormalities),
the sensitivity was 66.7% (CI-95%, 55.8-76.0), specificity was 91.2% (95% CI,
79.7-96.7), PPV was 92.3% (95% CI, 82.2-97.1), and NPV was 63.5% (95% CI,
51.9-73.5). CONCLUSIONS: The diagnostic power found in this study was similar to
the reported by Della-Porta et al. Also in LA, the analysis was made in modern
equipment with acquisition of at least 100 000 events which permits a good
reproducibility of the results.
